Methotrexate Ebewe (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is needed to produce tetrahydrofolate, a form of folate essential for making DNA, RNA, and proteins. By limiting these building blocks, the drug slows the division of rapidly proliferating cells, such as cancer cells and activated immune cells, thereby reducing disease activity.

The specific dose of Methotrexate Ebewe is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and treatment goals. Only a qualified healthcare professional can set the appropriate dosing regimen for each individual case.

Methotrexate is classified as teratogenic and is contraindicated in pregnancy because it can cause severe fetal malformations. Women of childbearing potential should use effective contraception. Limited data exist for breastfeeding, and the drug is generally avoided as it may be excreted in milk and affect the infant.

To request Methotrexate Ebewe, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Methotrexate belongs to the antimetabolite class, differing from alkylating agents or taxanes. It specifically targets folate metabolism, offering a distinct mechanism that can be advantageous in certain cancers and autoimmune diseases. Compared with newer biologics, methotrexate is less expensive but may require more laboratory monitoring for toxicity.

Methotrexate Ebewe should be stored at controlled room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency throughout its shelf life.

Methotrexate Ebewe is supplied for parenteral use and can be given via intra‑arterial, intramuscular, or intravenous injection, depending on the clinical indication and prescribing physician’s guidance. Administration should be performed by qualified healthcare professionals in a controlled setting.

The most serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening bone‑marrow suppression leading to infections or bleeding, and renal impairment. Patients should be monitored regularly for liver enzymes, lung function, blood counts, and kidney function to detect early signs of toxicity.

Methotrexate Ebewe is contraindicated in pregnant women, individuals with severe liver disease, uncontrolled infections, or significant renal impairment. Patients with known hypersensitivity to methotrexate or any component of the formulation should also avoid its use.